Accuray’s Bold Move: A Game Changer in Oncology?

Accuray’s Strategic Move into Emerging Markets Bolsters Outlook for Growth

Accuray Incorporated, a leading player in the radiation oncology sector, has garnered attention from investment firm Roth/MKM as it expands its presence in emerging markets. With a Buy rating assigned and a price target set at $9.00, Roth/MKM believes that Accuray’s current market share of 10% in the sector, along with its consistent cash generation, are positive indications of the company’s financial health.